ArticleProceedings of the National Academy of Sciences of the United States of America2024

Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2.

Heike Schönherr et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.